Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ToMeTuM

Financiado

Cerrado

Towards the Understanding a Metal Tumour Metabolism

A tumour cell uses both genetic and protein weapons in its development. Gaining a greater understanding of these lethal mechanisms is a key step towards developing novel and more effective treatments. Because the metal ion metabol... ver más

28/02/2023

BRNO UNIVERSITY OF...

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

VYSOKE UCENI TECHNICKE V BRNE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-02-28

ERC-2017-STG: ERC Starting Grant

I+D

Cerrada hace 8 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

BRNO UNIVERSITY OF TECHNOLOG...

1.38M€ | Lider

DYNAMIC CONSULTING INTERNATI...

558.27K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

MEMOTUMCELLMACH Metallodrugs to Modulate Tumour Cell Machinery 100K€ Cerrado

SAF2017-87358-C2-2-R LOS SISTEMAS DE UBIQUITIN LIGASAS SCFFBXW7 Y SCFBTRCP EN LAS... 73K€ Cerrado

SAF2012-34424 NUEVOS COMPLEJOS DE PLATINO CON ESTRUCTURAS NO CONVENCIONALE... 94K€ Cerrado

SAF2008-01845 ESTRATEGIAS ANTINEOPLASICAS BASADAS EN LA CARACTERIZACION ES... 182K€ Cerrado

Organomet Novel organometallic anticancer compounds 157K€ Cerrado

SAF2013-48657-R MODULACION DE LA PROGRESION TUMORAL POR ENZIMAS PI3K: APROXI... 484K€ Cerrado

Duración del proyecto: 63 meses Fecha Inicio: 2017-11-22
Fecha Fin: 2023-02-28

Líder del proyecto

VYSOKE UCENI TECHNICKE V BRNE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 1M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto A tumour cell uses both genetic and protein weapons in its development. Gaining a greater understanding of these lethal mechanisms is a key step towards developing novel and more effective treatments. Because the metal ion metabolism of a tumour cell is not fully understood, we will address the challenge of explaining the mechanisms of how a tumour cell copes both with essential metal ions and platinum based drugs. The metal-based mechanisms help a tumour to grow on one side and to protect itself against commonly used metal-based drugs. On the other side, the exact description of these mechanisms, which are being associated with multi-drug resistance occurrence and failure of a treatment, still remains unclear. We will reveal the mechanism of the as yet not understood biochemical and molecularly-biological relationships and correlations between metal ions and proteins in a tumour development revealing the way how to suppress the growth and development of a tumour and to markedly enhance the effectiveness of a treatment. To achieve this goal, we will focus on metallothionein and its interactions with essential metals and metal-containing anticancer drugs (cisplatin, carboplatin, and oxaliplatin). Their actions will be monitored both in vitro and in vivo. For this purpose, we will optimize electrochemical, mass spectrometric and immune-based methods. Based on processing of data obtained, new carcinogenetic pathways will be sought on cell level and proved by genetic modifications of target genes. The discovered processes and the pathways found will then be tested on two animal experimental models mice bearing breast tumours (MCF-7 and 4T1) and MeLiM minipigs bearing melanomas. The precise description of the tumour related pathways coping with metal ions based on metallothioneins will direct new highly effective treatment strategies. Moreover, the discovery of new carcinogenetic pathways will open a window for understanding of cancer formation and development.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores